Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Vicarious Surgical Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
9.8
22.1
43.9
47.6
40.2
33.6
Selling and marketing
0.86
2.96
6.46
6.23
4.53
2.17
General and administrative
2.33
13.2
29.7
26.9
21.9
15.2
Operating expenses
13
38.2
80.1
80.7
66.6
50
Operating income
-13
-38.2
-80.1
-80.7
-66.6
-50
Interest expense
0
0.09
0.2
0.03
Interest income
0.11
0.02
1.44
4.43
3.29
Other non-operating income
3.33
-0.16
Pre-tax income
-12.9
-35.2
5.16
-71.1
-63.2
-50.2
Net income
-12.9
-35.2
5.16
-71.1
-63.2
-50.2
EBITDA
-12.8
-37.9
-79
-78.8
-64.4
-48.6
EPS, basic
-0.16
-0.36
0.04
-0.49
EPS, diluted
-0.16
-0.36
0.04
-0.49
Shares, basic (weighted)
96.7
122
4.87
5.89
6.13
Shares, diluted (weighted)
78.7
96.7
128
4.87
5.89
6.13
Balance sheet
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
16.9
174
116
52.8
9.74
2.57
Short-term investments
45.4
39.4
7.22
Other current assets
0.26
4.87
4.2
2.78
2.6
1.79
Total current assets
17.1
178
120
101
51.7
11.6
Property, plant and equipment
0.45
2.25
6.59
6.4
4.48
1.27
Lease right-of-use assets
12.3
11.5
10.6
5.76
Other non-current assets
0.1
0.09
0.11
0.05
0.03
Total assets
17.8
182
140
120
67.7
19.6
Accounts payable
0.37
1.5
1.73
1.26
1.17
0.89
Accrued liabilities
0.39
4.1
5.81
4.98
5.28
1.06
Total current liabilities
0.81
6.25
8.39
7.28
7.67
3.9
Long-term debt
0.68
Lease liabilities
14.8
13.8
12.6
5.84
Total liabilities
0.94
98.6
29.2
21.9
21
9.74
Total debt
0.68
2
Paid-in capital
48.4
150
173
231
243
256
Retained earnings
-31.6
-66.8
-61.6
-133
-196
-246
Treasury stock
-90
-6.02
Other comprehensive income
0.01
0.05
0
Shareholders' equity
-29.8
83.1
111
98
46.7
9.84
Minority interests
18.9
Total equity
16.9
83.1
111
98
46.7
9.84
Total liabilities and equity
17.8
182
140
120
67.7
19.6
Cash flow statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-12.9
-35.2
5.16
-71.1
-63.2
-50.2
Depreciation and amortization
0.16
0.32
1.11
1.85
2.11
1.43
Stock-based compensation
0.45
3.69
12.3
13.3
11.9
8.14
Change in payables
1.13
0.14
-0.47
-0.1
-0.27
Cash from operations
-12
-33.3
-61.2
-62.3
-50
-45.1
Capital expenditures
-0.12
-1.29
-5.35
-1.67
-0.18
-0.13
Acquisitions
-1.2
Purchases of investments
-75.7
-58.1
-21.3
Cash from investing
13.2
-1.29
-5.35
-45.8
6.86
32.1
Stock issued
0.04
0.42
10
47
0.01
0.07
Cash from financing
13.5
192
9.15
44.7
0.01
5.76
Net change in cash
14.7
158
-57.4
-63.4
-43.1
-7.17
Free cash flow
-12.2
-34.6
-66.6
-64
-50.1
-45.2
Interest paid
0
0.04
0.04
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.06 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-177.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-115.0%
Net income / average total assets.
Return on invested capital (ROIC)
-178.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-78.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-55.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-71.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-48.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
1.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-63.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-40.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.97x
Current assets / current liabilities.
Quick ratio
2.51x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.51x
(Cash + short-term investments) / current liabilities.
Was Vicarious Surgical Inc. profitable in fiscal 2025?
No. It reported a net loss of $50.2M.
How much free cash flow did Vicarious Surgical Inc. generate in fiscal 2025?
Cash from operations of $45.1M minus capital expenditures of $132.0K left free cash flow of -$45.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.